The goal of this effort is to create and maintain state-of-the-art guidelines on the diagnosis and management of VWD.
PrintFriendly
-
NHF to Collaborate on Clinical Practice Guidelines for von Willebrand Disease
-
Update on Latest ACA Lawsuit
More information on how the current ACA lawsuit could affect the bleeding disorders community.
-
New Study on Cardiovascular Disease in Hemophilia Patients
Investigators looked into whether having hemophilia protected patients against cardiovascular disease.
-
Catalyst’s Trial Update Includes Reports of Antibody Responses
The update reported on a Phase 1/2 clinical trial for the company’s investigational therapy for the treatment of patients with severe hemophilia B/factor IX (FIX) deficiency.
-
Medical Advisory #424: Grifols Announces Recall of One Lot of Profilnine
Grifols Announces Recall of One Lot of Profilnine. This recall is being conducted as a precautionary measure.
-
Genentech Announces the Launch of New Safety Website
The new web portal for patients and caregivers is intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA.
-
HEMLIBRA® Granted Priority Review by FDA
This priority review is specifically for adults and children with hemophilia A without FVIII inhibitors.
-
FDA Approves New Vial Size for Idelvion®
The new vial size is 3500 IU (international unit).